Generated by AI
CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and other diseases. The company’s current work centers on immune-based treatments designed to help the body recognize and respond to disease, with research and development spanning oncology, autoimmune conditions, and infectious diseases. Its lead programs include Multikine, an investigational therapy for head and neck cancer, and the LEAPS platform, which supports the creation of targeted immune-modulating candidates. CEL-SCI also combines drug discovery, development, and manufacturing capabilities for complex biological substances, making it a specialized participant in the life sciences sector. Headquartered in Vienna, Virginia, CEL-SCI Corporation operates as a research-driven company within the biotechnology market, where its pipeline is aimed at advancing novel therapeutic approaches through immunology.
Website8229 Boone Boulevard
Vienna, VA, 22182
United States
The latest articles about CVM.
VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.
Summary of Nov 18's posts. Generated by AI.
Summary of Jan 22's posts. Generated by AI.
Summary of Oct 8's posts. Generated by AI.
Investors talking about CVM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.